Table 2.
Comparison between pre-clinical/clinical inhibitors and pomegranate/pomegranate compounds having STAT3 inhibitory potential.
| Inhibitor name |
Cancer |
Results |
References |
|---|---|---|---|
| Pre-clinical/clinical STAT3 inhibitors | |||
| PY*LKTK | NIH3T3/v-Src | Induce apoptosis, reduce cell proliferation, and decrease metastasis | [227] |
| Stattic | Breast cancer | [228] | |
| IS3-295 | Colon cancer | [229] | |
| S3I-1757 | Lung cancer | [230] | |
| Breast cancer | |||
| AZD9150 | Advanced/metastatic hepatocellular carcinoma | [231] | |
| AZD0530 | Melanoma | [232] | |
| DBD-1 | Melanoma | [233,234] | |
| Napabucasin | Hepatocellular carcinoma | [235] | |
| Colorectal carcinoma | |||
| GPA512 | Prostate cancer | [236] | |
| Pomegranate STAT3 inhibitors | |||
| Pomegranate extract | Prostate cancer | Reduce metastasis induce apoptosis, and inhibited cell proliferation | [33] |
| Ellagic acid | Cervical cancer | [225] | |
| Pomegranate fruit extract | Skin cancer | [226] | |
STAT3: Signal transducer and activator of transcription 3.